Q-omics provides the consensus-scored C22orf42 profile across patient tissues and cancer cell-line models. C22orf42 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C22orf42 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, C22orf42 RNA expression shows 8,468 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where C22orf42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C22orf42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C22orf42 survival associations across molecular data types. C22orf42 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C22orf42 RNA expression–survival associations across cancer types. High C22orf42 expression shows unfavorable associations in ACC, LIHC, KIRC, DLBC and LAML, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for C22orf42 RNA expression.
This table summarizes C22orf42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C22orf42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C22orf42 shows lower tumor expression in BRCA and STAD and higher tumor expression in KIRC, HNSC, ESCA and BLCA. The KIRC box plot shows higher C22orf42 RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p < 0.001).
This table shows molecular features associated with C22orf42 in patient tissues and cancer cell lines. In patient samples, C22orf42 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C22orf42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
